Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4830631> ?p ?o }
Showing triples 1 to 73 of
73
with 100 triples per page.
- Q4830631 subject Q52309.
- Q4830631 subject Q6973246.
- Q4830631 subject Q7335370.
- Q4830631 subject Q8297683.
- Q4830631 subject Q8543773.
- Q4830631 subject Q8636858.
- Q4830631 abstract "Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.".
- Q4830631 atcPrefix "L01".
- Q4830631 atcSuffix "XE17".
- Q4830631 bioavailability "58.0".
- Q4830631 casNumber "319460-85-0".
- Q4830631 chEBI "66910".
- Q4830631 fdaUniiCode "C9LVQ0YUXG".
- Q4830631 iupacName "N-Methyl-2-3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide".
- Q4830631 pubchem "6450551".
- Q4830631 thumbnail Axitinib2DACS.svg?width=300.
- Q4830631 wikiPageWikiLink Q1129111.
- Q4830631 wikiPageWikiLink Q1164529.
- Q4830631 wikiPageWikiLink Q130146.
- Q4830631 wikiPageWikiLink Q1332167.
- Q4830631 wikiPageWikiLink Q14864419.
- Q4830631 wikiPageWikiLink Q14890102.
- Q4830631 wikiPageWikiLink Q14901445.
- Q4830631 wikiPageWikiLink Q14916187.
- Q4830631 wikiPageWikiLink Q16833590.
- Q4830631 wikiPageWikiLink Q177094.
- Q4830631 wikiPageWikiLink Q17912018.
- Q4830631 wikiPageWikiLink Q17928830.
- Q4830631 wikiPageWikiLink Q17928864.
- Q4830631 wikiPageWikiLink Q18028241.
- Q4830631 wikiPageWikiLink Q180664.
- Q4830631 wikiPageWikiLink Q1916302.
- Q4830631 wikiPageWikiLink Q204711.
- Q4830631 wikiPageWikiLink Q206921.
- Q4830631 wikiPageWikiLink Q20969938.
- Q4830631 wikiPageWikiLink Q212961.
- Q4830631 wikiPageWikiLink Q288322.
- Q4830631 wikiPageWikiLink Q30612.
- Q4830631 wikiPageWikiLink Q4056087.
- Q4830631 wikiPageWikiLink Q414143.
- Q4830631 wikiPageWikiLink Q421136.
- Q4830631 wikiPageWikiLink Q4356503.
- Q4830631 wikiPageWikiLink Q52309.
- Q4830631 wikiPageWikiLink Q539568.
- Q4830631 wikiPageWikiLink Q55505.
- Q4830631 wikiPageWikiLink Q593277.
- Q4830631 wikiPageWikiLink Q6973246.
- Q4830631 wikiPageWikiLink Q7202242.
- Q4830631 wikiPageWikiLink Q7251487.
- Q4830631 wikiPageWikiLink Q729735.
- Q4830631 wikiPageWikiLink Q7335370.
- Q4830631 wikiPageWikiLink Q8297683.
- Q4830631 wikiPageWikiLink Q8543773.
- Q4830631 wikiPageWikiLink Q8636858.
- Q4830631 wikiPageWikiLink Q906415.
- Q4830631 wikiPageWikiLink Q9368.
- Q4830631 atcPrefix "L01".
- Q4830631 atcSuffix "XE17".
- Q4830631 bioavailability "58.0".
- Q4830631 casNumber "319460".
- Q4830631 chebi "66910".
- Q4830631 iupacName "N-Methyl-2-3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide".
- Q4830631 pubchem "6450551".
- Q4830631 unii "C9LVQ0YUXG".
- Q4830631 type ChemicalSubstance.
- Q4830631 type Drug.
- Q4830631 type ChemicalObject.
- Q4830631 type Thing.
- Q4830631 type Q8386.
- Q4830631 comment "Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.".
- Q4830631 label "Axitinib".
- Q4830631 seeAlso Q17014601.
- Q4830631 depiction Axitinib2DACS.svg.